利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

5 条记录 (耗时 0.015 秒)

    MATERIALS AND METHODS FOR DIAGNOSIS AND PROGNOSIS OF LIVER CANCER
    1.
    发明申请
    MATERIALS AND METHODS FOR DIAGNOSIS AND PROGNOSIS OF LIVER CANCER 审中-公开
    用于肝癌诊断和预防的材料和方法

    公开(公告)号：US20160320395A1

    公开(公告)日：2016-11-03

    申请号：US15036773

    申请日：2014-11-13

    申请人： ELECTROPHORETICS LIMITED ,  KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST

    发明人： Malcolm Andrew Ward ,  Ian Hugo Pike ,  David James Britton ,  Vikram Mitra ,  Nigel David Heaton ,  Yoh Zen ,  Alberto Quaglia

    IPC分类号： G01N33/574 ,  G06F19/18

    CPC分类号： G01N33/57438 ,  G01N33/57423 ,  G01N2800/52 ,  G01N2800/60 ,  G16B20/00

    摘要： The invention relates to materials and methods for diagnosing liver tumor types, and assessing patient prognosis. Specifically, but not exclusively, the invention concerns the determination of marker protein which enable primary liver tumors to be identified and classified according to the latest WHO classification. Particularly, the invention provides potential markers proteins which allow non-neoplastic and neoplastic hepatocytes and biliary epithelial cells to be distinguished. This allows grading of tumor differentiation to be refined and differential diagnosis of primary liver tumors and pathogenesis of sub-types of cholangiocarcinoma.

    摘要翻译： 本发明涉及用于诊断肝肿瘤类型的材料和方法，以及评估患者预后。 具体地，但不排他地，本发明涉及可以根据最新的WHO分类鉴定和分类原发性肝肿瘤的标记蛋白的确定。 特别地，本发明提供潜在的标记蛋白，其允许区分非肿瘤性和肿瘤性肝细胞和胆道上皮细胞。 这允许细分肿瘤分化和原发性肝肿瘤的鉴别诊断和胆管癌的亚型的发病机制。

    BIOMARKERS AND METHODS RELATING TO ALZHEIMER'S DISEASE
    3.
    发明申请
    BIOMARKERS AND METHODS RELATING TO ALZHEIMER'S DISEASE 审中-公开

    公开(公告)号：US20170219611A1

    公开(公告)日：2017-08-03

    申请号：US15104149

    申请日：2014-12-12

    申请人： Electrophoretics Limited ,  King's College London

    发明人： Malcolm Andrew Ward ,  Abdul Hye ,  Simon Harold Lovestone ,  Richard James Butler Dobson

    IPC分类号： G01N33/68

    CPC分类号： G01N33/6896 ,  G01N2800/2814 ,  G01N2800/2821 ,  G01N2800/52

    摘要： Alzheimer's disease, the most common cause of dementia in older individuals, is a debilitating neurodegenerative disease for which there is currently no cure. In the past, AD could only be definitively diagnosed by brain biopsy or upon autopsy after a patient died. These methods, which demonstrate the presence of the characteristic plaque and tangle lesions in the brain, are still considered the gold standard for the pathological diagnoses of AD. However, in the clinical setting brain biopsy is rarely performed and diagnosis depends on a battery of neurological, psychometric and biochemical tests, including the measurement of biochemical markers such as the ApoE and tau proteins or the beta-amyloid peptide in cerebrospinal fluid and blood. The present invention discloses and describes panels of makers that are differentially expressed in the disease state relative to their expression in the normal state and, in particular, identifies and describes panels of makers associated with neurocognitive disorders. Such biomarker panel might have considerable value in triaging patients with early memory disorders to yet more specific but more invasive and costly approaches such as molecular markers in CSF and on PET imaging in clinical trials and possibly in clinical practice.

    METHODS AND COMPOSITIONS RELATING TO NEURODEGENERATIVE DISEASES
    4.
    发明申请
    METHODS AND COMPOSITIONS RELATING TO NEURODEGENERATIVE DISEASES 审中-公开
    与神经病变疾病相关的方法和组合

    公开(公告)号：US20160139151A1

    公开(公告)日：2016-05-19

    申请号：US14896018

    申请日：2014-06-06

    申请人： Electrophoretics Limited

    发明人： Malcolm Andrew Ward ,  Hui-Chung Liang ,  Ian Hugo Pike

    IPC分类号： G01N33/68

    CPC分类号： G01N33/6896 ,  C12Q1/34 ,  G01N33/6842 ,  G01N2333/775 ,  G01N2400/00 ,  G01N2440/38 ,  G01N2458/15 ,  G01N2800/28 ,  G01N2800/2814 ,  G01N2800/2821 ,  G01N2800/2835 ,  G01N2800/52 ,  G01N2800/60

    摘要： The present invention provides a method for diagnosing or assessing a neurodegenerative disease in a test subject, comprising: (i) providing a protein-containing sample that has been obtained from the test subject; (ii) determining the concentration, amount or degree of expression of at least one specific protein isoform and/or glycoform derived from a protein biomarker selected from the group consisting of: clusterin precursor; apolipoprotein A-IV precursor; apolipoprotein C-III precursor; transthyretin; galectin 7; complement C4 precursor; alpha-2-macroglobulin precursor; Ig alpha-1 chain C; histone 2B; Ig lambda chain C region; fibrinogen gamma chain precursor; complement factor H; inter-alpha-trypsin heavy chain H4 precursor; complement C3 precursor; gamma or beta actin; haptoglobin precursor; and the serum albumin precursor, or a fragment thereof; (iii) comparing said concentration, amount or degree determined in (ii) with a reference from a control subject with a specific neurodegenerative disease, dementia or stage of disease, or from a control subject that does not have a neurogenerative disease or dementia; and (iv) based on the level of the at least one specific protein isoform and/or glycoform of the protein biomarker in the test subject relative to the reference, making a diagnosis or assessment as to the presence of and/or stage of neurodegenerative disease or dementia of the test subject. Also provided are related products and systems for use in such a method.

    摘要翻译： 本发明提供了一种用于诊断或评估测试对象中的神经变性疾病的方法，包括：（i）提供从测试对象获得的含蛋白质的样品; （ii）确定衍生自选自以下的蛋白质生物标志物的至少一种特异性蛋白质同种型和/或糖型的浓度，量或程度：簇蛋白前体; 载脂蛋白A-IV前体; 载脂蛋白C-III前体; 转甲状腺素 半乳凝素7; 补体C4前体; α-2-巨球蛋白前体; Igα-1链C; 组蛋白2B; Igλ链C区; 纤维蛋白原γ链前体; 补体因子H; α-胰蛋白酶重链H4前体; 补体C3前体; γ或β肌动蛋白; 触珠蛋白前体; 和血清白蛋白前体，或其片段; （iii）将来自（ii）中确定的所述浓度，量或程度与具有特定神经变性疾病，痴呆或疾病阶段的对照受试者或不具有神经生长性疾病或痴呆的对照受试者的参考比较; 和（iv）基于测试对象相对于参考的蛋白质生物标志物的至少一种特异性蛋白质同种型和/或糖型的水平，对神经变性疾病的存在和/或阶段进行诊断或评估 或测试对象的痴呆症。 还提供了用于这种方法的相关产品和系统。